NCT03477110 is a EARLY_PHASE1 clinical trial of Temozolomide in Glioblastoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT03477110?

Interventions in NCT03477110: Temozolomide, Radiation Therapy, NovoTTF-200A Device, Tumor Treating Fields Therapy.

What condition does NCT03477110 study?

NCT03477110 studies Glioblastoma.

Is NCT03477110 still recruiting?

NCT03477110 is currently completed. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT03477110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Completed EARLY_PHASE1 Last updated 15 May 2025

What this trial tests

EARLY_PHASE1 trial testing Temozolomide in Glioblastoma in 30 participants. Completed in 26 January 2024.

Timeline

4 May 2018

Primary endpoint
21 April 2021

26 January 2024

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	4 May 2018
Primary completion	21 April 2021
Estimated completion	26 January 2024
Sites	1 location across United States

Drugs / interventions tested

Temozolomide (temozolomide) — full drug profile →
Radiation Therapy — full drug profile →
NovoTTF-200A Device
Tumor Treating Fields Therapy

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot early phase I trial studies the side effects of temozolomide, radiation therapy, and tumor treating fields therapy using Novo tumor treatment fields (TTF)-200A device in participants with glioblastoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. NovoTTF-200A device is a portable device that produces alternating electrical fields that may disrupt growth of cancer cells. Giving temozolomide, radiation therapy, and tumor treating fields therapy using NovoTTF-200A device may work better in treating participants with glioblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.
Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, et al · · 2019 · cited 163× · PMID 30717372 · DOI 10.3390/cancers11020174
Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP, Shin D, Melnick K, Tran DD. · · 2020 · cited 79× · PMID 32734509 · DOI 10.1007/s11864-020-00773-5
Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
Wu H, Yang L, Liu H, Zhou D, et al · · 2021 · cited 38× · PMID 34710276 · DOI 10.1111/cns.13750
Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment.
Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, et al · · 2020 · cited 29× · PMID 33215030 · DOI 10.3389/fonc.2020.575992
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
Miller R, Song A, Ali A, Niazi M, et al · · 2022 · cited 22× · PMID 35574391 · DOI 10.3389/fonc.2022.896246
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A, Bar-Ad V, Martinez N, Glass J, et al · · 2020 · cited 22× · PMID 32206976 · DOI 10.1007/s11060-020-03466-z
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.
Khagi S, Kotecha R, Gatson NTN, Jeyapalan S, et al · · 2025 · cited 20× · PMID 39401002 · DOI 10.1093/oncolo/oyae227
Enhancing glioblastoma treatment through the integration of tumor-treating fields.
Szklener K, Bilski M, Nieoczym K, Mańdziuk D, et al · · 2023 · cited 20× · PMID 37916157 · DOI 10.3389/fonc.2023.1274587

Verify or expand the search:

Other trials of Temozolomide

Trials testing the same drug.

NCT04373785 — NG101m Adjuvant Therapy in Glioblastoma Patients · Phase 1, PHASE2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07452458 — Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, ID · Phase 3 · not yet recruiting
NCT06639607 — PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/Hi · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03477110 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03477110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing